Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) heightens infection risk via immune dysregulation, repeated device exposure, and dialysis care. Although HD and CAPD pose access-related threats, dialysis patients also present with other diseases. In Indonesia, dialysis antibiograms are scarce, limiting empiric therapy and stewardship. We analyzed cultures and antimicrobial susceptibility testing (AST) from CKD patients on dialysis to map organism distribution by modality and specimen, quantify resistance to key agents, and identify clinical predictors of resistance to guide empiric choices.
Single-center retrospective cross-sectional study at Dr H Abdul Moeloek General Hospital Lampung (Jan 2024–Aug 2025). We include adults (≥18 y) with CKD on dialysis with positive cultures and AST; excluded no-culture records, non-clinically relevant contaminants, and duplicate isolates. The resistance rate was % resistant among isolates tested for an antibiotic. Logistic regression per antibiotic assessed associations between resistance (outcome) and age, gender, dialysis modality, specimen type, organism, and comorbidities; results as OR (95% CI), p-values.
We get 80 culture-positive isolate records from on dialysis CKD patients (71 HD, 9 CAPD). Specimens are accumulated from 13.75% CDL swab, 11.25% CAPD fluid , 23.75% pus, 16.25% blood, 25.00% sputum, 2.50% urine and 7.50% other body fluids. This shows infections come beyond access sites only. K. pneumoniae (15.0%), E. coli (13.75%), and S. aureus (13.75%) are the leading pathogens found from all isolates. In catheter-related infections, CDL samples showed S. epidermidis (27.27%, 95% CI 0.09–0.59) as most common organism, while K. pneumoniae (33.33%, 95% CI 0.11–0.67) and S. hominis (33.33%, 95% CI 0.11–0.67) were the main contributor in CAPD samples.
Resistance patterns vary by organism. We observed very high resistance to 3rd-generation cephalosporins and fluoroquinolones (≈90–100%) but remained fully susceptible to carbapenems and amikacin in E. coli. While K. pneumoniae shows moderate–high resistance to ceftriaxone (58.3%) and aztreonam (66.7%), but lower aminoglycoside resistance (16.7%). Half of S. aureus was MRSA (oxacillin/cefoxitin 50%) with vancomycin still susceptible and low clindamycin(9.1%) and erythromycin(18.2%) resistance.
In exploratory modeling, organism type was the principal driver of resistance, though most organisms–antibiotic effects had wide confidence intervals. The most reliable association was lower tetracycline resistance in S. epidermidis (OR 0.012, 95% CI 0.0003–0.49; p=0.020). Dialysis modality and specimen type showed no independent association with resistance.
Infections in CKD dialysis patients come from both catheter related or non related sources. K. pneumoniae, E. coli, and S. aureus are most common organisms. The resistance landscape showed high β-lactam and fluoroquinolone resistance in Enterobacterales and persistent MRSA. Organism type showed significant relations to resistance rather than dialysis modality or specimen source. The importance of empirical therapy based on organisms are highlighted in these findings and the need for dialysis-related antibiograms to optimize outcomes in interconnected kidney care.
